

Cervical Intraepithelial Neoplasia (CIN) (Women's and Male Health) - Drugs in Development, 2021

<https://marketpublishers.com/r/C68F95E30D5EEN.html>

Date: December 2021

Pages: 335

Price: US\$ 2,000.00 (Single User License)

ID: C68F95E30D5EEN

Abstracts

Cervical Intraepithelial Neoplasia (CIN) (Women's and Male Health) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2021, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty-five to thirty-five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research

and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 19, 4 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 4, 2, 1 and 3 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Cervical Intraepithelial Neoplasia (CIN) - Overview
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
- Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
- Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
- Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
- Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Better Life Pharmaceuticals Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Blue Sky Immunotherapies GmbH, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Gilead Sciences Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by KinoPharma Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Merck & Co Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Novan Inc, 2021

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Nykode Therapeutics AS, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Papivax LLC, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc (Inactive), 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccitech Plc, 2021
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by ViciniVax BV, 2021
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2021
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Cervical Intraepithelial Neoplasia (CIN) (Women's and Male Health) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/C68F95E30D5EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C68F95E30D5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

